Latest News

Latest News

If you're a media professional and would like more information about MSD in Ireland, please contact our Corporate Communications Manager who will be happy to support your query.

Barbara Coyle

Ph: + 353 86 8371701
E: barbara.coyle@merck.com

 

You can also find more information about MSD in Ireland here.

For the Corporate Headquarter News, please click here.
 

MSD and Takeda conclude acquisition of Dunboyne manufacturing site

______________________________________________________________________________________

21 Sept 2020: 

Dunboyne Co. Meath, Ireland, September 21, 2020 - MSD has concluded the acquisition of the Dunboyne manufacturing facility of Takeda Dunboyne Biologics Limited, a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (”Takeda”), it was announced today.  The state-of-the-art, flexible manufacturing facility, which will now be known as MSD Dunboyne Biologics, has been acquired as a going concern and the 200 employees associated with the site have concluded the consultation process and will now join MSD Ireland’s existing 2,500 strong workforce. The divestment agreement was first announced in August 2020 (see here) .

Thomas Wozniewski, Takeda Global Manufacturing & Supply Officer, commented: “We are pleased that we can announce the conclusion of the divestment of the Dunboyne Biologics plant. Both teams have done tremendous work in delivering the necessary work in a short time. With MSD, we believe we have found a company that is most suitable for the Dunboyne facility and we expect a great future for the Dunboyne team. We wish the departing Dunboyne team every success within the MSD network.”

Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD, commented: “We are delighted to welcome the Dunboyne site to the MSD network and we look forward to working with the site leadership team and all of the existing employees to collectively realise the full potential of the facility. The Dunboyne facility will play an important role in MSD’s existing manufacturing network, both in Ireland and globally, helping to make the medicines of tomorrow that will positively impact patients globally. The addition of this state-of-the-art facility will further expand our significant manufacturing presence across Ireland and will complement the work already underway across our five sites here.  Our existing Irish sites play a pivotal role in manufacturing some of our company’s most significant medicines and vaccines and I look forward to enhancing our operations even further with the addition of this new facility and its talented team to our network.”   

Commenting on the announcement An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar T.D, said “This is good news for Meath. Today’s decision gives staff security after what has been an undoubtedly stressful time and paves the way for future development of the site. I wish MSD the very best with the venture.” 

CEO of IDA Ireland, Martin Shanahan said: “I would like to congratulate both parties on the conclusion of the acquisition of the Dunboyne manufacturing facility.  This acquisition allows MSD to further develop the site and secures the employment of the 200 staff onsite.  MSD is a leading global pharmaceutical company with a long track record of successful operations in Ireland. The company is a substantial and valued employer whose commitment to Ireland is evidenced by the significant capital investment it has made over the years in its different sites here.”

ENDS


NOTES TO EDITORS:
In January 2020, Takeda announced its intention to divest of its Dunboyne Biologics facility. The divestment decision followed a strategic review of the Takeda global biologics manufacturing network, initiated following the acquisition of Shire, which identified that production capacity at Dunboyne would no longer be required. Takeda immediately commenced a divestment process to seek the most suitable buyer for the facility, as a going concern. Following an intensive sales process over the past months, Takeda has reached agreement with MSD to acquire the facility.

MEDIA CONTACTS

Takeda 
Freeha Rafiq
Head of Communications & Patient Advocacy, UK and Ireland
Tel: +44 (0)750 095 3471
Email: freeha.rafiq@takeda.com

FTI Consulting (Takeda)
Jonathan Neilan
Tel: +353 86 231 4135 
Email: Jonathan.Neilan@fticonsulting.com

MSD Ireland
Barbara Coyle
Corporate Communications Manager
Tel: +353 86 837 1701
Email: barbara.coyle@merck.com

About Takeda 

Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader committed to bringing better health and a brighter future to patients by translating science into life-changing medicines, has been established in Ireland since 1997. Across Ireland, Takeda has commercial operations, corporate services and two manufacturing facilities in Bray and Grange Castle.
www.takeda.com/en-ie

About MSD

MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), is one of Ireland’s leading healthcare companies, currently employing over 2,500 people across its existing five sites. MSD’s operations in Ireland play a significant role in the company’s global network, exporting to more than 60 countries worldwide. For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. 
www.msd-ireland.com

https://msd-ireland.com/resources/press_releases/FINAL_-_Press_Release_-Dunboyne_Agreement_Conclusion.pdf

 

MSD and Takeda announce future of Dunboyne manufacturing site

______________________________________________________________________________________

7 Aug 2020: 

Dunboyne Co. Meath, Ireland, August 7, 2020 - MSD has entered into an agreement for the acquisition of the Dunboyne manufacturing facility of Takeda Dunboyne Biologics Limited, a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (”Takeda”), it was announced today. Subject to completion activities, including the engagement with the employees based at the site and final due diligence steps, the agreement will see the state-of-the-art, flexible manufacturing facility acquired as a going concern. Takeda will now embark upon a consultation period with approximately 200 employees of the Dunboyne site and the process is expected to conclude by mid-September.

Thomas Wozniewski, Takeda Global Manufacturing & Supply Officer, commented: “We are pleased to announce the divestment of the Dunboyne Biologics plant to MSD who will retain all of our existing Dunboyne employees. In MSD, we believe we have found the most suitable buyer for the Dunboyne facility, offering a great perspective for our Dunboyne team. We sincerely thank the team in Dunboyne for its work and dedication in preparing this world-class facility for production. With operations in Baggot Street, Bray, and Grange Castle, Ireland remains a key country within Takeda’s global manufacturing network.”

Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD, commented: “We are delighted to have signed this agreement to acquire the Dunboyne Biologics facility and look forward to working with the team to support the next phase of this process. This facility will further expand our footprint in Ireland and support commercialisation of our existing and future pipeline of biologics products. The talent of the team in Dunboyne was a determining factor in our decision to acquire this facility and we look forward to welcoming our new colleagues to the broader MSD Ireland network, building on the progress they have made to date and, together, realising the potential of this facility for the benefit of patients in Ireland and globally.”

Susan Hynes, Site Lead, Dunboyne Biologics, commented: “This is a very exciting day for our employees at Dunboyne. Our dedicated team of champions have delivered a state-of-the-art biologics facility with leading edge technology ready to serve future MSD patients across the world. We believe the announcement today demonstrates the confidence that MSD has that the facility, capabilities and culture we have at Dunboyne will thrive in the new organisation and support long term growth for the company. As we prepare for our long-term future in Dunboyne, we also look forward to further strengthening the close relationship the team already has with the local community.”

ENDS

NOTES TO EDITORS:
In January 2020, Takeda announced its intention to divest of its Dunboyne Biologics facility. The divestment decision followed a strategic review of the Takeda global biologics manufacturing network, initiated following the acquisition of Shire, which identified that production capacity at Dunboyne would no longer be required. Takeda immediately commenced a divestment process to seek the most suitable buyer for the facility, as a going concern. Following an intensive sales process over the past months, Takeda has reached agreement with MSD to acquire the facility.

MEDIA CONTACTS

Takeda
Freeha Rafiq
Head of Communications & Patient Advocacy, UK and Ireland
Tel: +44 (0)750 095 3471
Email: freeha.rafiq@takeda.com

FTI Consulting (Takeda)
Jonathan Neilan Tel: +353 86 231 4135
Email: Jonathan.Neilan@fticonsulting.com

MSD Ireland
Barbara Coyle
Corporate Communications Manager
Tel: +353 86 837 1701
Email: barbara.coyle@merck.com

About Takeda

Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader committed to bringing better health and a brighter future to patients by translating science into life-changing medicines, has been established in Ireland since 1997. Across Ireland, Takeda has commercial operations, corporate services and two manufacturing facilities in Bray and Grange Castle.
www.takeda.com/en-ie

About MSD Ireland

MSD Ireland is one of Ireland’s leading healthcare companies, currently employing over 2,500 people across its existing five sites. MSD’s operations in Ireland play a significant role in the company’s global network, exporting to more than 60 countries worldwide. For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.
www.msd-ireland.com

https://msd-ireland.com/resources/press_releases/7th_August_2020_-_Dunboyne_Biologics_Facility_Acquisition.pdf

 

Transfer of Values Figures
______________________________________________________________________________________

17 Apr 2019:

MSD has conducted a thorough assessment into the recent issue whereby MSD figures reported on the Irish Transfer of Value (TOV) website were incorrect. 

The cause of this issue was an error in uploading the data that resulted in all of MSD’s payments being increased by a factor of 100.   The incorrect data were posted on the TOV site from February 27, 2019 until April 12, 2019, a period of approximately 6 weeks. The correct data has now been published on the Transfer of Values website, www.transferofvalue.ie

We sincerely apologise that this error occurred and we have implemented a number of measures to ensure this situation does not arise again.  This week, we will write to all those healthcare professionals and organisations affected to ensure they are aware of the issue and the steps we have taken to rectify this matter. 

MSD is committed to accurately reporting this information and is fully committed to providing transparency around our company interactions with key stakeholders. 

We would ask any Healthcare Professionals or Healthcare Organisations who may have queries and concerns on this issue to contact us directly at transparency@msd.ie.